Author

J. Zorea

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

M. Elkabets· 2 shared Y. Carmi· 2 shared A. Karabajakian· 1 shared A. Mock· 1 shared A. Shnerb· 1 shared B. Joshua· 1 shared B. Rotblat· 1 shared D. Kong· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. Elkabets

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TRAF3 Suppression Encourages B Cell Recruitment and Prolongs Survival of Microbiome-Intact Mice with Ovarian Cancer

J. Zorea, Y. Motro, R. Mazor, Y. Carmi, Z. Shulman, J. Mahajna, J. Moran-Gilad, M. Elkabets

This study identifies TRAF3 as a tumor-derived immune suppressor in ovarian cancer, showing its role in inhibiting B-cell infiltration and that microbiota presence is required for B-cell activation and tumor progression.

bioRxiv · Feb 9, 2023 · PreprintCancer Biology

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

M. Prasad, J. Zorea, S. Jagadeeshan, A. Shnerb, J. Bouaoud, L. Michon, O. Novoplansky, M. Badarni, L. Cohen, K. Yagodayev, S. Tzadok, B. Rotblat, L. Brezina, A. Mock, A. Karabajakian, , M. Elkabets

This study shows that MEK1/2 inhibition temporarily improves the tumor immune microenvironment, enhancing immunotherapy effectiveness in head and neck cancer by reducing suppressive myeloid cells and boosting CD8+ T cell activity.

bioRxiv · Aug 22, 2021Cancer Biology